SEC Form 4 · accession 0001209191-15-040442
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Officer — CEO & Executive Chariman · Director
Period of report
May 6, 2015
Accepted (ET)
May 8, 2015 · 2:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $14.00 | May 6, 2015 | A | 163,437 | A | — | May 6, 2025 | Common Stock | 163,437 | 163,437 | D |
Explanation of responses
- F1The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on May 6, 2015, such that this option is fully exercisable on May 6, 2019. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F2Not applicable.